Overview

KRN7000 in Treating Patients With Solid Tumors

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as KRN7000 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of KRN7000 in treating patients who have solid tumors that have not responded to previous treatment.
Phase:
Phase 1
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Treatments:
KRN 7000